PUBLISHER: The Business Research Company | PRODUCT CODE: 1425393
PUBLISHER: The Business Research Company | PRODUCT CODE: 1425393
Digestive and Intestinal Remedies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on digestive and intestinal remedies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digestive and intestinal remedies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The digestive and intestinal remedies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Digestive and intestinal remedies encompass medications designed to address gastrointestinal disorders, including issues like stomach upset, constipation, and diarrhea. The treatment process often involves the use of drug classes such as antacids, proton pump inhibitors, and histamine2 blockers.
The main types of digestive and intestinal remedies include digestive medicines, remedies targeting gastrointestinal complaints, and both natural and synthetic agents. Digestive medicines include compounds like digestive enzymes, which aid the body in breaking down and digesting meals. These medicines are particularly helpful in treating occasional heartburn, nausea, and upset stomach. They cater to various age groups, including pediatric and adult populations, and are distributed through various channels, such as online and offline platforms.
The digestive and intestinal remedies market research report is one of a series of new reports from The Business Research Company that provides digestive and intestinal remedies market statistics, including digestive and intestinal remedies industry global market size, regional shares, competitors with a digestive and intestinal remedies market share, detailed digestive and intestinal remedies market segments, market trends and opportunities, and any further data you may need to thrive in the digestive and intestinal remedies industry. This digestive and intestinal remedies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digestive and intestinal remedies market size has grown strongly in recent years. It will grow from $20.51 billion in 2023 to $21.63 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth observed in the historical period can be attributed to factors such as the use of traditional remedies, lifestyle changes, increased stress levels, dietary shifts, and the impact of the COVID-19 pandemic.
The digestive and intestinal remedies market size is expected to see strong growth in the next few years. It will grow to $27.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The anticipated growth in the forecast period can be attributed to factors such as improved healthcare accessibility, the influence of global health events, an increasing health consciousness among the population, the impact of an aging demographic, and ongoing innovation in product development. Major trends in the forecast period encompass healthcare access, considerations of environmental factors, consumer education initiatives, changes in the regulatory environment, and advancements in the pharmaceutical industry.
The digestive and intestinal remedy market is expected to experience growth due to the increase in gastrointestinal disorder cases. Gastrointestinal disorders, including conditions like nausea, vomiting, food poisoning, and diarrhea, have seen a rising incidence, leading to an amplified demand for effective remedies. For example, the prevalence of Inflammatory Bowel Disease (IBD) is anticipated to significantly increase in various regions by 2035, according to a report by BioMed Central. The projected rise in gastrointestinal disorders, including IBD, is a key driver propelling the growth of the digestive and intestinal remedy market.
The digestive and intestinal remedy market is expected to benefit from the growth of telemedicine services. The expanded availability of telemedicine services provides individuals with digestive and intestinal issues convenient access to healthcare consultations and advice without physical visits. This fosters early intervention and management of disorders, driving an increased demand for relevant remedies and medications. With 37.0% of adults in the United States having utilized telemedicine services in 2021, as reported by the Centers for Disease Control and Prevention, the growing adoption of telemedicine is a significant factor driving the digestive and intestinal remedy market.
Technological developments and advancements emerge as a key trend in the digestive and intestinal remedy market. Major players in the market are focusing on innovative technologies to manage and monitor digestive health, including the use of breath analyzers for gathering clinical condition information related to the digestive system. Owlstone Medical's collaboration with functional gut diagnostics and functional gut clinic to launch digestive health breath testing showcases the application of advanced technologies in the market. Breath testing, as an emerging and precise method, demonstrates how technological advancements contribute to the digestive and intestinal remedy market's growth.
Major companies operating in the digestive and intestinal remedy market are developing innovative products, including digital platforms, to reach larger customer bases, drive more sales, and increase revenue. Digital platforms, such as Owlstone Medical's OMED Health, empower patients to comprehend their gut microbiome and effectively manage their digestive well-being. OMED Health focuses on digestive ailments and aims to enhance the quality of life for individuals by providing improved and expedited understanding and control of their conditions. The utilization of digital platforms in the form of online technology-based systems for monitoring and regulating symptoms is contributing to the growth and competitiveness of the digestive and intestinal remedy market.
In November 2022, Biocodex Group, a healthcare company based in France, successfully acquired Hilma for an undisclosed amount. This strategic acquisition is anticipated to enable Hilma to rapidly expand its omnichannel retail strategy, access new demographics, and foster innovation in product development. The decision to sell by Hilma was driven by the extensive global scale offered by Biocodex, a valuable asset in overcoming the challenges associated with growing a digitally-native brand in the current business landscape. These challenges include managing heightened marketing expenses, addressing logistical complexities, and recruiting specialists for wholesale account expansion. Hilma, the acquired company, is a US-based provider specializing in natural remedies. The acquisition reflects Biocodex's commitment to strengthening its position in the healthcare market and leveraging its global presence for the benefit of Hilma's growth and development.
Major companies operating in the digestive and intestinal remedies market report are Bayer AG, Abbott Laboratories, Bausch Health Companies Inc., CH Boehringer Sohn AG & Co. KG, Eli Lilly and Company, GlaxoSmithKline PLC, Jiangzhong Pharmaceutical Co. Ltd., Johnson & Johnson Pvt. Ltd., Menarini Group, Merck Co. & KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Alfa Wassermann and Sigma-Tau, Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Chemical Pharma Co. Ltd., Evoke Pharma Inc., Ipsen SA, Ironwood Pharmaceuticals Inc., Mundipharma, Mylan NV, Norgine Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Perrigo Company, Recordati S.p.A., RedHill Biopharma Ltd., Ritter Pharmaceuticals Inc., and Salix Pharmaceuticals Inc.
North America was the largest region in the digestive and intestinal remedies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digestive and intestinal remedies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digestive and intestinal remedies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The digestive and intestinal remedies market consists of sales of antacids, prokinetic agents, laxatives, antidiarrheal agents, generic enzymes. Values in this market are ''''factory gate'''' values that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.